All articles — 4016 total
Olenox Industries enters the week carrying two simultaneous shocks: a subsidiary bankruptcy and a confirmed reverse stock split — and short sellers have been covering fast. The most striking move in the data is the…
UroGen Pharma heads into its May 11 earnings report with short sellers pulling back even as the stock's structural bear case remains firmly intact. The most striking feature of the past month is the divergence between…
Viridian Therapeutics enters its May 7 earnings call riding one of the sharpest weekly moves in the biotech universe — up 38% in five sessions to $18.75, with a single-day gain of 33% on May 5 doing almost all the…
Adient reported Q2 fiscal 2026 earnings on May 6, landing into a market where six weeks of short covering have materially changed the positioning picture. Short sellers have been in steady retreat. Short interest as a…
ABI just delivered its most rewarding single day in months — and the borrow market has taken notice. Q1 results dropped on May 5, and they were unambiguously strong. Revenue hit $15.27 billion, up from $13.63 billion…
Protagonist Therapeutics enters the post-earnings window with a meaningful gap between what the numbers delivered and what the options market had priced for disaster. The company reported Q1 2026 results on May 5,…
Madrigal Pharmaceuticals posted Q1 2026 results today that landed above expectations on both lines — yet the stock fell 3% on the session to close at $502.47, and is down nearly 9% over the past month. The disconnect…
Johnson Controls International reported a clean Q2 beat on May 6, yet the stock barely moved — and that gap between solid fundamentals and muted market reaction is the most interesting thing about the setup right…
ATKR enters the post-earnings window with a fresh tailwind — a Q2 beat and same-day target upgrades — even as the headline numbers still show a wider net loss year-on-year. The earnings release, filed before the open…
RACE fell 4.1% on the week to close at €279.55, even as the company delivered a strong first-quarter report and reaffirmed its full-year outlook — a gap between fundamentals and price that frames the most interesting…
Alkermes entered May with a catalyst in hand. Q1 results dropped on May 5, topping both revenue and earnings estimates, and the stock responded with a 6% gain on the day. The question now is whether the renewed analyst…
Avalo Therapeutics lit up screens this week. Positive Phase 2 LOTUS trial data for AVTX-009 — its lead IL-1β inhibitor targeting hidradenitis suppurativa — sent the stock up 18% on Tuesday and 26% on the week to…
LivaNova is heading into a fresh quarter under genuine short-selling pressure, with short interest climbing more than 20% over the past month while the stock has dropped to its lowest close in nearly a year. Short…
Performance Food Group heads into May with short sellers retreating and the Street remaining firmly constructive — yet the stock trades almost 26% below where analysts have it priced. The most interesting tension…
Lumentum Holdings enters the post-earnings window as one of the week's standout performers in photonics, with a 25.7% surge closing at $994.56 — a move that appears to have left short sellers scrambling and analysts…
PayPal enters the week under twin pressure — a post-earnings selloff and a fresh UK regulatory investigation — while short sellers are quietly reducing their bets. The price action this week tells the most urgent…
Kraft Heinz enters its May 14 Q1 earnings report with short sellers quietly adding pressure — and a Street that has been cutting targets for months, leaving analysts neutral at best heading into the print. Short…
TopBuild Corp. enters the post-earnings period in an unusual position: the stock has surged 20% in a month, short sellers have largely fled, and yet analysts are cutting ratings, not raising them. The driver is the…
CC arrived at its Q1 2026 earnings release riding a 30% one-month rally — and then promptly fell back as the results hit the tape. The week captured a classic pre-earnings long squeeze in reverse. The stock closed at…
Spyre Therapeutics heads into its May 8 earnings call in a charged position — the Street is racing to lift targets after strong Phase 2 data, while the CEO, CFO, and CMO all hit the sell button on the same day the…
